CompletedPhase 2NCT00890162
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
Studying Non-histaminic angioedema
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Melody C Carter, M.D.National Institute of Allergy and Infectious Diseases (NIAID)
- Intervention
- Epinephrine(drug)
- Enrollment
- 16 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2009 – 2019
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00890162 on ClinicalTrials.gov